Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Angiodynamics Inc Reaffirms FY 2013 Guidance; Lowers FY 2013 Revenue And EBITDA Guidance


Thursday, 3 Jan 2013 04:01pm EST 

Angiodynamics Inc announced that for fiscal 2013, it expects adjusted non-GAAP to be in the range of $355-$360 million, non-GAAP operating income to be in a range of $29-$31 million, non-GAAP EBITDA to be in a range of $56-$57 million and non-GAAP earnings per share (EPS) to be in a range $0.40-$0.42. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $360 million, EBIT of $30 million, EBITDA of $57 million and EPS of $0.40 for fiscal 2013. 

Company Quote

13.87
-0.12 -0.86%
24 Apr 2014